There's Still No Pill for Cocaine. The Treatment That Works Pays You Instead — and Most States Won't Cover It.

Twice a week, in clinics that run this program right, someone sits down, hands over a urine cup, and waits eleven minutes for a strip to turn one color or two. If it comes back negative, they reach into a fishbowl of folded slips of paper. Most say “good job.” Some are worth a few dollars. A few are worth a hundred. That is, in its most literal form, the best-evidenced treatment in America for cocaine and methamphetamine addiction: contingency management, structured incentives for a verified negative test, and there is nothing else in the pharmacy that comes close.

The country has spent forty years and hundreds of millions of dollars looking for a pill to treat stimulant addiction, and it does not exist. Not for cocaine. Not for methamphetamine. The FDA’s own announcement on advancing novel stimulant use disorder therapies is itself the clearest confirmation of the gap it’s trying to close: the agency is still working on encouraging development of a medication, in 2026, for a class of drugs that CDC’s National Center for Health Statistics put behind roughly a third of all U.S. overdose deaths as recently as 2023 — nearly 35,000 deaths involving psychostimulants like methamphetamine, and nearly 30,000 involving cocaine, with heavy overlap between the two categories and with fentanyl. The same CDC data brief carries real, hard-won good news: those death rates fell sharply in 2024, down almost 20% for psychostimulants and nearly 27% for cocaine. That drop is a reason for real hope. It is not a reason to stop building the treatment infrastructure — a falling death rate from a drug supply nobody controls is not the same thing as a solved addiction. Methadone exists for opioids. Buprenorphine exists for opioids. Naltrexone exists for both opioids and alcohol. For stimulants, the cabinet is empty.

What isn’t empty is the evidence for contingency management itself. The American Psychological Association’s Monitor on Psychology reported this year that CM is now the American Society of Addiction Medicine’s designated standard of care for stimulant use disorder — the behavioral-health equivalent of a first-line drug. Decades of trials back it. It is cheap, it is simple, and it does not require a chemist to invent anything new. What it requires is money to pay for the incentives and a payer willing to reimburse for delivering it. That’s where the story turns from a medical success into a policy failure.

The treatment works. The federal government still treats it as an experiment.

Medicaid is the country’s largest single payer for addiction treatment, and Medicaid does not, as a rule, cover contingency management. Not because CMS doubts the evidence — the opposite. According to KFF’s tracking of Section 1115 demonstration waivers, the only route a state Medicaid program has to cover CM at all is to apply for special federal permission to waive the ordinary rules and run it as a demonstration. Five states — California, Delaware, Hawaii, Montana, and Washington — have gotten that permission approved. A handful more have applications pending. Everyone else is stuck.

Translate that out of policy-speak: if you have cocaine or methamphetamine use disorder and you’re on Medicaid in most of the country, the treatment your own federal agency calls the standard of care is not something your insurance is allowed to pay for. It isn’t banned because it’s dangerous or unproven. It’s blocked because of an accounting rule that treats paying someone $75 to stay clean as more suspicious, procedurally, than paying a hospital $75,000 to treat the overdose that follows when nothing else was covered. The National Health Law Program’s brief on CM and Medicaid and a companion analysis in the Health Law & Policy Brief both land on the same diagnosis: the barrier here is bureaucratic, not clinical. That distinction matters, because bureaucratic barriers are the ones a state legislature or a CMS administrator can remove without waiting on a single new clinical trial.

We have watched this exact shape of resistance before. In 1986, Congress passed the Anti-Drug Abuse Act and set a 100-to-1 sentencing disparity between crack cocaine and powder cocaine — the same drug, prosecuted as though it were two different crimes, driven by fear of a “crack epidemic” more than by pharmacology. It took until the Fair Sentencing Act of 2010 to narrow that ratio to 18-to-1, and by then a generation had already served the difference in federal prison. The pattern is the same one running through contingency management today: cocaine has always drawn a country readier to punish it than to treat it, and even when the treatment shows up, evidence-backed and federally endorsed, it still has to fight for permission to exist. The drug changed color. The reflex didn’t.

Why paying someone to test negative is not a bribe — it’s how the brain relearns

Here’s the part that gets lost every time contingency management shows up in a headline reduced to “cash for staying clean”: it isn’t a bribe, and it isn’t really about the money. Stimulant use disorder rewires the brain’s dopamine reward circuit so that the drug itself becomes the fastest, most reliable source of a reward signal the brain has learned to crave on a schedule. Psychologists have a name for what CM does to counter that — operant conditioning, pairing a healthy behavior with an immediate, tangible reward — but you don’t need the term to understand the mechanism: it gives the brain a second fast, reliable reward it can get from not using, on the same kind of immediate schedule the drug had already trained it to expect. That’s why abstinence-only counseling alone struggles against stimulants in a way it doesn’t against every substance — there’s no medication doing the slow work in the background, so the incentive structure itself has to do double duty.

That mechanism is also why trial design matters, and why a JAMA Psychiatry–reported analysis covered by Psychiatry Advisor argues that stimulant pharmacotherapy trials may be underselling real benefit by grading success only on total abstinence. A person who cuts their methamphetamine use by two-thirds without hitting zero has a measurably lower overdose risk and a measurably different life — but a strict abstinence endpoint records that person as a treatment failure. If the same recalibration that’s helping CM’s evidence base — measuring what actually reduces harm, not just what hits a clean binary — gets applied to pharmacotherapy research too, some of the “failed” cocaine and meth medication trials of the last twenty years might look different in hindsight. Right now, though, medication is still not the tool on the table. CM is.

Right now, though, medication is still not the tool on the table.

If you’re the one sitting across from a case manager with a fishbowl on the table, none of the policy mechanics matter until they show up as a program you can actually walk into. You already know CM sounds too simple to be a real treatment — that’s the same reaction most people in the field had, until they saw the retention numbers. The honest caveat, the one a clinician would want named alongside the good news: CM’s effect is strongest for the duration people stay enrolled, and what happens to those gains after incentives stop is still an active research question, not a settled one. That’s not a reason to withhold it. It’s a reason to fund it long enough to find out.

What a state can do this year, without Congress

For a provider or a case manager reading this Thursday morning, the actionable version is narrower than “reform Medicaid”: it’s find out whether your state has an active or pending 1115 waiver, and if it doesn’t, whether your state behavioral health authority has a public comment process for one. The Center for Health Care Strategies’ CM resource is written explicitly for state Medicaid staff who are trying to build a waiver application, with the implementation detail — incentive caps, verification protocols, fraud safeguards — that turns “we should cover this” into an actual state plan amendment. If you sit in a team meeting this week, the question worth raising isn’t whether CM works. It’s whether your state has even started the paperwork.

None of this changes what’s true right now for a person using cocaine or methamphetamine today: naloxone still won’t reverse a stimulant-only overdose the way it reverses an opioid one, but fentanyl-adulterated stimulant supply is common enough that carrying naloxone and never using alone are still the two things most likely to keep you alive between now and whenever a program like this reaches you. Those two things are still yours, free, regardless of what your state’s Medicaid office has or hasn’t approved.

Forty years of failed pharmacology trials taught the field something true and uncomfortable: for stimulants, there may never be a methadone. What there is, already proven, already cheap, already sitting in a fishbowl on a table in five states, is a treatment that works because it meets a rewired brain on its own terms and gives it something to want that isn’t the drug. The remaining question was never scientific. It’s whether the other forty-five states decide that’s worth the paperwork.